DCE-254 is an EZH2 inhibitor (IC50 = 11 μM) with significant antiproliferative activity against lymphoma cell lines; it suppresses the development of hypermethylation-associated cancers by inhibiting S-adenosylmethionine (SAM)-mediated methyltransferase activity (IC50 = 10.3 μM).